Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
December 19 2017 - 08:00AM
Business Wire
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay
B. Siegall, Ph.D., President and Chief Executive Officer, will
present at the 36th Annual J.P. Morgan Healthcare Conference on
Monday, January 8, 2018 at 10:30 a.m. Pacific Time. Both the
presentation and question and answer session that follows at 11:00
a.m. will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegenetics.com in the Investors
section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company
dedicated to improving the lives of people with cancer through
novel antibody-based therapies. The company’s industry-leading
antibody-drug conjugate (ADC) technology harnesses the targeting
ability of antibodies to deliver cell-killing agents directly to
cancer cells. Seattle Genetics commercializes ADCETRIS®
(brentuximab vedotin) for the treatment of several types of
CD30-expressing lymphomas. The company is also advancing a robust
pipeline of novel therapies for solid tumors and blood-related
cancers designed to address significant unmet medical needs and
improve treatment outcomes for patients. More information can be
found at www.seattlegenetics.com and follow @SeattleGenetics on
Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171219005304/en/
Seattle Genetics, Inc.Investors:Peggy Pinkston,
425-527-4160ppinkston@seagen.comorMedia:Brandi Robinson,
425-527-2910brobinson@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024